Nevertheless, this newfound appreciation of the link between EGFR inhibitors and the immune system provides novel insights into how EGFR antagonists may function during cancer treatment, permiting adjustments to our current use of these drugs in the clinic. The gene discussed is EGFR; the disease is cancer.